Clinical trial
Multicentre, Randomised, Double-blind, Parallel-group, Phase III Study to Evaluate the Genetic Polymorphism Influence in the Response to Ranibizumab and Bevacizumab Treatment in Patients With Age-Associated Macular Degeneration.
NCT06952452 is registered in ClinicalTrials.gov with Parc de Salut Mar as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicentre, Randomised, Double-blind, Parallel-group, Phase III Study to Evaluate the Genetic Polymorphism Influence in the Response to Ranibizumab and Bevacizumab Treatment in Patients With Age-Associated Macular Degeneration.
- Lead sponsor
- Parc de Salut Mar
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- November 18, 2022
- Completion date
- July 31, 2026
- Enrollment
- 630 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
wet age-related macular degeneration